SHANGHAI FOSUN PHARMACEUTICAL Aktie

 

FOSUN INTL (00656.HK) announced that its subsidiary FOSUN PHARMA (02196.HK), through its wholly-owned subsidiary Fosun Pharma Singapore, sold a total of 9.897 million shares in Gland Pharma Limited via block trades and open market bidding, representing approximately 6% of the company's total shares. The total consideration ......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

SHANGHAI, Sept. 6, 2026 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) today announced an H-share repurchase plan, under which the company intends to repurchase its H-shares with an aggregate amount of up to HK$1 billion.......

FOSUN PHARMA (02196.HK) announced that Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a subsidiary of the company, received approval from the National Medical Products Administration for the drug registration application of FCN-159 tablets, with the trade name Fumeining, for a new indication. The newly approved ......

Pivotal 480-patient trial met all primary and secondary efficacy and safety endpoints after a single treatment cycle, with the primary responder rate showing a 30-percentage-point advantage over placebo; NDA submission to China's regulator planned by year-end 2026, with Fosun preparing a......

FOSUN PHARMA (02196.HK) announced its interim results for the six months ended June. Revenue rose 4.9% YoY to RMB20.377 billion. Gross profit increased 8.5% to RMB10.088 billion. Net profit amounted to RMB1.721 billion, up 1.1% YoY, with EPS of RMB0.65. No dividend was declared. (d)~AASTOCKS Financial NewsWebsite: www.aastocks.c......

Globalization Accelerates Value Realization of Innovative Drugs SHANGHAI, Aug. 25, 2026 /PRNewswire/ -- On August 25, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its interim results for 2026. In the first half of 2026 ("the Reporting Period", or 1H2026), the......

FOSUN PHARMA (02196.HK) announced that FXR0906 injection, a liver-targeted siRNA innovative drug for the treatment of hypertriglyceridemia (HTG), recently completed dosing of the first participant in a Phase I clinical trial in China.FXR0906 is a liver-targeted siRNA innovative drug that precisely silences APOC3 gene expression ......

FOSUN PHARMA (02196.HK) announced that its subsidiary has initiated a Phase II clinical trial in China for FXS7553 for the treatment of chronic obstructive pulmonary disease.FXS7553 is a self-developed small-molecule oral DPP-1 inhibitor of the group, intended for the treatment of non-cystic fibrosis bronchiectasis, chronic obst......

FOSUN PHARMA (02196.HK) announced that the drug registration application for Dobutamine Hydrochloride Injection submitted by its controlling subsidiary Shanghai Chaohui has been approved by the National Medical Products Administration. The approved indication is for heart failure caused by decreased myocardial contractility in o......

FOSUN PHARMA (02196.HK) announced that the drug registration application for the additional indication of Luvometinib Tablets has been approved by the National Medical Products Administration (NMPA). The approved indication is for the treatment of pediatric patients 2 years of age and older with relapsed or refractory Langerhans......

FOSUN PHARMA (02196.HK)'s controlling subsidiary Fosun Antengene plans to issue new shares to four investors, representing approximately 12.15% of the total enlarged share capital after the capital increase, raising RMB968 million (same below). Among them, external investors plan to subscribe for a total of RMB418 million, while......

FOSUN PHARMA (02196.HK) announced that its innovative oncology immunotherapy FXB0871 has completed dosing of the first participant in a Phase I clinical trial in China (excluding Hong Kong, Macau and Taiwan). FXB0871 is a PD-1-targeted attenuated IL-2 fusion protein immunotherapy (ATTENUKINE) jointly developed by FOSUN PHARMA an......

FOSUN PHARMA (02196.HK) announced that it officially signed a strategic cooperation framework agreement with GENRIX (688443.SH). The two parties will establish a long-term, stable and mutually trusting strategic partnership to accelerate the research and development and commercialization of innovative drugs, and jointly enhance ......

SHANGHAI and SEONGNAM, South Korea, May 13, 2026 /PRNewswire/ -- On 13 May, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) and AriBio Co., Ltd. ("AriBio"), a biopharmaceutical company focused on neurodegenerative diseases, today jointly......

CLSA issued a report stating that FOSUN PHARMA (02196.HK)'s results for 1Q26 slightly missed market expectations. Although revenue and profit recorded solid growth, mainly driven by the innovative drug segment, the healthcare services segment continued to face pressure. Nevertheless, management remains confident in achieving the......

SHANGHAI, April 28, 2026 /PRNewswire/ -- On 28 April, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its results for the first quarter of 2026 (the reporting period). During the reporting period, the Company achieved a total revenue of RMB 10,073 million,......

FOSUN PHARMA (02196.HK) announced its first-quarter results, with revenue of RMB10.073 billion, up 6.9% YoY. Net profit attributable to shareholders amounted to RMB871 million, representing a 13.9% YoY increase. EPS was RMB0.33. (de/d)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by A......

Strategic framework established for regional and global licensing, frontier technology incubation, and strategic collaboration in neurodegenerative diseases Joint R&D aligned with China-UAE bilateral partnership and Abu Dhabi's Healthcare Life Sciences Vision 2030 SHANGHAI, April 28, 2026......

Morgan Stanley said in a research report that it raised Fosun Pharma (02196.HK)'s revenue forecasts for 2026 to 2028 by 3%, driven by higher sales of innovative drugs and expected recurring licensing income of approximately RMB800 million per year.Meanwhile, it lowered net profit forecasts by 1%, 1% and raised by 4%, respectivel......